S-1 Filing

GP-Act III Acquisition initially filed for an offering of $250 million in March 2021. The SPAC revised its prospectus several times before withdrawing an IPO in November 2022.

The new SPAC said it will focus on the aerospace and defense services industries, particularly companies contributing to the global aerospace and defense economy. 

The SPAC had a deal with NaturalShrimp, but the seafood company terminated the merger agreement in July last year.

Biotech Group had planned to focus on the biotechnology sector in North America and the Asia-Pacific region (excluding China, Hong Kong and Macau).

In addition to founding his previous Churchill Capital SPACs, CEO, President and Director Michael Klein was previously CEO of Global Banking at Citi.

The SPAC's last amended filing, in December, reduced the offering from the original 10 million units initially registered with the SEC in November 2021.

The SPAC had planned to focus on high-growth software and technology-enabled companies that are disrupting large and established industries and markets.

The new SPAC said it will target the deep technology sector in Asia, including AI, quantum computing, and biotechnology.

 "We intend to focus our search initially on target businesses operating in Asia, and we may consummate a business combination with an entity located in the People’s Republic of China (including Hong Kong and Macau)," the new SPAC said in the filing.

The SPAC will focus on potential acquisition targets that exhibit compelling long-term growth potential and highly defensible market positions.